These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15664721)

  • 1. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
    Marsch LA; Bickel WK; Badger GJ; Jacobs EA
    Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
    Petry NM; Bickel WK; Badger GJ
    Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between low-magnitude voucher and buprenorphine medication contingencies in promoting abstinence from opioids and cocaine.
    Gross A; Marsch LA; Badger GJ; Bickel WK
    Exp Clin Psychopharmacol; 2006 May; 14(2):148-56. PubMed ID: 16756418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
    Bell J; Byron G; Gibson A; Morris A
    Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
    Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
    Fhima A; Henrion R; Lowenstein W; Charpak Y
    Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
    Foltin RW; Fischman MW
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1153-64. PubMed ID: 8819498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine: an alternative to methadone for heroin dependence treatment.
    Resnick RB; Galanter M; Pycha C; Cohen A; Grandison P; Flood N
    Psychopharmacol Bull; 1992; 28(1):109-13. PubMed ID: 1609035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase I safety evaluation.
    Teoh SK; Mendelson JH; Mello NK; Kuehnle J; Sintavanarong P; Rhoades EM
    J Clin Psychopharmacol; 1993 Apr; 13(2):87-99. PubMed ID: 8463453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial.
    Chawarski MC; Mazlan M; Schottenfeld RS
    Drug Alcohol Depend; 2008 Apr; 94(1-3):281-4. PubMed ID: 18164145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres.
    Leonardi C; Hanna N; Laurenzi P; Fagetti R;
    Drug Alcohol Depend; 2008 Apr; 94(1-3):125-32. PubMed ID: 18162330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.
    Strain EC; Moody DE; Stoller KB; Walsh SL; Bigelow GE
    Drug Alcohol Depend; 2004 Apr; 74(1):37-43. PubMed ID: 15072805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial.
    Bell JR; Ryan A; Mutch C; Batey R; Rea F
    Drug Alcohol Depend; 2008 Jul; 96(1-2):183-6. PubMed ID: 18423901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrice-weekly versus daily buprenorphine maintenance.
    Schottenfeld RS; Pakes J; O'Connor P; Chawarski M; Oliveto A; Kosten TR
    Biol Psychiatry; 2000 Jun; 47(12):1072-9. PubMed ID: 10862807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans.
    Amass L; Bickel WK; Crean JP; Blake J; Higgins ST
    Psychopharmacology (Berl); 1998 Apr; 136(3):217-25. PubMed ID: 9566806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.